Plasma Concentration Studies
LY3437943
GLP-3
A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.
Third Party Tested by Freedom Diagnostics
Technical specifications
Avoid freeze/thaw cycles
Protect from light
Keep refrigerated
Lyophilized (powder)
-20°C • 24+ months
Reconstituted
2-8°C • ~30 days
Peer-reviewed research
New England Journal of Medicine
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023 • DOI: 10.1056/NEJMoa2301972
Jastreboff AM, et al.
The Lancet
Retatrutide for People with Type 2 Diabetes — A Phase 2 Trial
2023
Rosenstock J, et al.
Nature Medicine
Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
2024
Sanyal AJ, et al.
Lancet Diabetes & Endocrinology
Effects of Retatrutide on Body Composition
2025
Coskun T, et al.
PubMed Central
Triple Agonism Based Therapies for Obesity
2025
PubMed Central
Retatrutide — A Game Changer in Obesity Pharmacotherapy
2025
PubMed Central
Efficacy and Safety of Retatrutide — Systematic Review & Meta-Analysis
2024
Eli Lilly
TRIUMPH-4 Phase 3 Trial Results
2025
Nature Cell Discovery
Structural Analysis of Incretin Receptor Agonists
2024
PubChem Database
Retatrutide Compound Information
2025
ClinicalTrials.gov
Retatrutide Clinical Trials Registry
2025
